Some big news in the world of IgA Nephropathy treatment. IgA Nephropathy finally has a targeted therapy!
On December 15th, Calliditas Therapeutics announced the accelerated approval of TARPEYO (which was trialed under the name NEFECON).
Hopefully this is only the first of several such announcements to come over the next couple years as more trials advance towards completion. This is big not just for IgAN but for all the Nephrotic Syndrome related diseases such as FSGS and Minimal Change Syndrome that have similar trials in the pipeline.

A cure is the ultimate goal!

I should also reiterate my plea that if you are a patient please consider applying to a clinical trial if one is available in your area. The biggest challenge for clinical trials for rare diseases is finding patients that qualify and are available. It’s very difficult to reach the required number of participants to make it work, so every patient matters. More information on current trials can be found at https://kidneyhealthgateway.com/trials-research/.

Please check out the official announcement from Calliditas Therapeutics below. The drug should be available to patients early in 2022.

https://www.calliditas.se/en/fda-grants-calliditas-therapeutics-accelerated-approval-of-tarpeyo-budesonide-to-reduce-proteinuria-in-iga-nephropathy-3927/